- Home
- RNXT vs KYNB Comparison
RNXT vs KYNB Comparison
Compare RNXT & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | KYNB |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 31.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RNXT | KYNB |
|---|---|---|
| Price | $0.86 | $7.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.25 | N/A |
| AVG Volume (30 Days) | ★ 305.0K | 13.5K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,123,000.00 | N/A |
| Revenue This Year | $194.66 | N/A |
| Revenue Next Year | $279.78 | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | ★ 2511.63 | N/A |
| 52 Week Low | $0.70 | $6.32 |
| 52 Week High | $1.45 | $9.58 |
Technical Indicators
Market Signals| Indicator | RNXT | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 37.99 | 47.49 |
| Support Level | $0.82 | $6.67 |
| Resistance Level | $1.07 | $7.50 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 9.83 | 12.93 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.